Silexion Therapeutics (SLXN) Competitors $0.84 -0.05 (-5.07%) Closing price 02/21/2025 03:56 PM EasternExtended Trading$0.80 -0.04 (-5.20%) As of 02/21/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends SLXN vs. RDHL, GLTO, APM, VRAX, CMND, SNGX, ONVO, ABVC, ALZN, and FRTXShould you be buying Silexion Therapeutics stock or one of its competitors? The main competitors of Silexion Therapeutics include RedHill Biopharma (RDHL), Galecto (GLTO), Aptorum Group (APM), Virax Biolabs Group (VRAX), Clearmind Medicine (CMND), Soligenix (SNGX), Organovo (ONVO), ABVC BioPharma (ABVC), Alzamend Neuro (ALZN), and Fresh Tracks Therapeutics (FRTX). These companies are all part of the "pharmaceutical products" industry. Silexion Therapeutics vs. RedHill Biopharma Galecto Aptorum Group Virax Biolabs Group Clearmind Medicine Soligenix Organovo ABVC BioPharma Alzamend Neuro Fresh Tracks Therapeutics Silexion Therapeutics (NASDAQ:SLXN) and RedHill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, community ranking, dividends, profitability, analyst recommendations, institutional ownership and valuation. Which has better earnings and valuation, SLXN or RDHL? RedHill Biopharma has higher revenue and earnings than Silexion Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilexion TherapeuticsN/AN/A$260KN/AN/ARedHill Biopharma$6.53M0.93$23.92MN/AN/A Do insiders and institutionals hold more shares of SLXN or RDHL? 11.0% of Silexion Therapeutics shares are owned by institutional investors. Comparatively, 7.2% of RedHill Biopharma shares are owned by institutional investors. 33.0% of Silexion Therapeutics shares are owned by company insiders. Comparatively, 6.8% of RedHill Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community prefer SLXN or RDHL? RedHill Biopharma received 426 more outperform votes than Silexion Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Silexion Therapeutics an outperform vote while only 66.82% of users gave RedHill Biopharma an outperform vote. CompanyUnderperformOutperformSilexion TherapeuticsOutperform Votes1100.00% Underperform VotesNo VotesRedHill BiopharmaOutperform Votes42766.82% Underperform Votes21233.18% Does the media refer more to SLXN or RDHL? In the previous week, RedHill Biopharma had 1 more articles in the media than Silexion Therapeutics. MarketBeat recorded 1 mentions for RedHill Biopharma and 0 mentions for Silexion Therapeutics. Silexion Therapeutics' average media sentiment score of 0.00 equaled RedHill Biopharma'saverage media sentiment score. Company Overall Sentiment Silexion Therapeutics Neutral RedHill Biopharma Neutral Do analysts rate SLXN or RDHL? Silexion Therapeutics presently has a consensus price target of $9.00, suggesting a potential upside of 965.21%. Given Silexion Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Silexion Therapeutics is more favorable than RedHill Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00RedHill Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, SLXN or RDHL? Silexion Therapeutics has a beta of 0.02, meaning that its share price is 98% less volatile than the S&P 500. Comparatively, RedHill Biopharma has a beta of 3.68, meaning that its share price is 268% more volatile than the S&P 500. Is SLXN or RDHL more profitable? Company Net Margins Return on Equity Return on Assets Silexion TherapeuticsN/A N/A -249.43% RedHill Biopharma N/A N/A N/A SummarySilexion Therapeutics and RedHill Biopharma tied by winning 6 of the 12 factors compared between the two stocks. Get Silexion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLXN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLXN vs. The Competition Export to ExcelMetricSilexion TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.49M$3.12B$5.85B$9.15BDividend YieldN/A1.56%4.76%3.85%P/E RatioN/A10.3116.5114.19Price / SalesN/A327.11450.0276.60Price / Cash1.46168.8538.0134.95Price / Book-0.133.687.644.63Net Income$260,000.00-$71.72M$3.18B$245.69M7 Day Performance-21.77%-2.46%-1.95%-2.68%1 Month Performance13.91%-0.25%-0.23%-2.16%1 Year PerformanceN/A-12.31%16.69%12.90% Silexion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLXNSilexion TherapeuticsN/A$0.84-5.1%$9.00+965.2%N/A$7.49MN/A0.00N/ARDHLRedHill Biopharma0.5846 of 5 stars$5.28-1.6%N/A-98.6%$6.75M$6.53M0.00210Positive NewsGLTOGalecto3.0977 of 5 stars$4.78+4.4%$10.00+109.2%-73.3%$6.31MN/A-0.2540APMAptorum Group0.5007 of 5 stars$1.19-0.8%N/A-38.1%$6.16M$430,000.000.0030Gap UpVRAXVirax Biolabs Group0.8513 of 5 stars$1.90+1.3%N/A+93.9%$6.15M$160,000.000.005CMNDClearmind MedicineN/A$1.41+0.7%N/A-27.9%$6.02MN/A-0.75N/AGap UpSNGXSoligenix1.2055 of 5 stars$2.39-2.8%N/A-79.1%$6.00M$840,000.00-0.3220News CoverageONVOOrganovo1.1238 of 5 stars$0.39+2.1%N/A-63.1%$5.93M$110,000.00-0.3620Earnings ReportABVCABVC BioPharma1.1237 of 5 stars$0.46+8.9%N/A-41.2%$5.93M$150,000.00-0.5330News CoveragePositive NewsGap DownHigh Trading VolumeALZNAlzamend Neuro2.6053 of 5 stars$1.09+0.9%$32.00+2,835.8%-88.9%$5.92MN/A0.004Gap UpFRTXFresh Tracks TherapeuticsN/A$0.93-0.3%N/A-1.1%$5.55M$8.01M-0.6620 Related Companies and Tools Related Companies RedHill Biopharma Alternatives Galecto Alternatives Aptorum Group Alternatives Virax Biolabs Group Alternatives Clearmind Medicine Alternatives Soligenix Alternatives Organovo Alternatives ABVC BioPharma Alternatives Alzamend Neuro Alternatives Fresh Tracks Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SLXN) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silexion Therapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Silexion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
